Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP8VDT)

• Drug Name: Elaidoylamide Drug Info
• Synonyms: Oleamide; Oleic acid amide; 301-02-0; Oleylamide; Oleyl amide; Adogen 73; Crodamide O; Slip-eze; Armoslip CP; Crodamide OR; cis-9,10-Octadecenoamide; (Z)-9-OCTADECENAMIDE; (9Z)-octadec-9-enamide; 9-Octadecenamide, (Z)-; (Z)-octadec-9-enamide; ELAIDOYLAMIDE; 9Z-octadecenamide; 9,10-octadecenamide; Unislip 1759; Kemamide O; Petrac Slip-Eze; UNII-7L25QK8BWO; Armid O; Amide O; trans-9,10-octadecenoamide; cis-9-Octadecenamide; 9-Octadecenamide, (9Z)-; 14C-labeled oleamide; Diamide O 200; HSDB 5560; (9E)-OCTADEC-9-ENAMIDE; oleamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5283387
  ChEBI ID: CHEMBL116314
  CAS Number: CAS 301-02-0
  TTD Drug ID: DMP8VDT

Molecule-Related Drug Atlas

Drug(s) Targeting Group IIA phospholipase A2 (GIIA sPLA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KH064	DMR1NYF	Breast cancer	2C60-2C65	Clinical trial	[4]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
Lauric Acid	DM9C8KQ	Discovery agent	N.A.	Investigative	[1]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[5]
2-(4-phenoxyphenoxy)ethanamine	DM7TBUJ	Discovery agent	N.A.	Investigative	[6]
CACOSPONGIONOLIDE	DMIPJUS	Discovery agent	N.A.	Investigative	[7]
Cacospongionolide E	DM2DYAV	Discovery agent	N.A.	Investigative	[7]
N-Tridecanoic Acid	DMNZ37C	Discovery agent	N.A.	Investigative	[5]
CACOSPONGIONOLIDE B	DMCSXNW	Discovery agent	N.A.	Investigative	[7]
BOLINAQUINONE	DMVB6UG	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting 5-HT 7 receptor (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[9]
JNJ-18038683	DMV1T59	Major depressive disorder	6A70.3	Phase 2	[10]
AVN-101	DMOGFNI	Cognitive impairment	6D71	Phase 2	[11]
ATI-9242	DM6GKMU	Schizophrenia	6A20	Phase 1	[12]
PMID30124346-Compound-34TABLE4	DM2G3VE	Attention deficit hyperactivity disorder	6A05.Z	Patented	[13]
PMID30124346-Compound-13TABLE4	DMHTJVA	Attention deficit hyperactivity disorder	6A05.Z	Patented	[13]
Carbamide derivative 2	DMW5GI3	N. A.	N. A.	Patented	[14]
4-oxadiazole derivative 1	DMWFHKR	N. A.	N. A.	Patented	[14]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[15]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[16]

Drug(s) Affected By Collagen alpha-1(I) chain (COL1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[17]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[18]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[19]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[20]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[21]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[22]
Ceruletide	DM2WE5K	Caerulein stimulated gastric and pancreatic secretion	5A4Y	Approved	[23]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[24]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[25]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 7 receptor (HTR7)	TTO9X1H	5HT7R_HUMAN	Modulator (allosteric modulator)	[2]
Group IIA phospholipase A2 (GIIA sPLA2)	TTO8QRU	PA2GA_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem Pharmacol. 1999 Dec 1;58(11):1807-13.
• [3] Gap junction communications influence upon fibroblast synthesis of Type I collagen and fibronectin. J Cell Biochem. 2006 Jul 1;98(4):735-43. doi: 10.1002/jcb.20852.
• [4] D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5.
• [5] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [6] Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
• [7] A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
• [8] New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
• [11] AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
• [12] Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
• [13] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [14] Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
• [15] [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
• [16] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [17] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [18] Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021 Jun;109:103673. doi: 10.1016/j.jdent.2021.103673. Epub 2021 Apr 16.
• [19] Patterns of some extracellular matrix gene expression are similar in cells from cleft lip-palate patients and in human palatal fibroblasts exposed to diazepam in culture. Toxicology. 2009 Mar 4;257(1-2):10-6. doi: 10.1016/j.tox.2008.12.002. Epub 2008 Dec 9.
• [20] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [21] Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
• [22] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [23] Acinar cell-specific knockout of the PTHrP gene decreases the proinflammatory and profibrotic responses in pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2014 Sep 1;307(5):G533-49. doi: 10.1152/ajpgi.00428.2013. Epub 2014 Jul 17.
• [24] The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Joint Surg Am. 2001 Feb;83(2):201-11. doi: 10.2106/00004623-200102000-00007.
• [25] Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006 Apr;54(4):1298-308. doi: 10.1002/art.21723.
• [26] Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy. Invest Ophthalmol Vis Sci. 2012 Aug 31;53(9):5921-9. doi: 10.1167/iovs.12-9646.